JAMA ginkgo debate
This article was originally published in The Tan Sheet
Executive Summary
"Outcome trials should use cognitive tests that are sensitive to ginkgo's pharmacologic mode of action in the brain," say Pradeep Nathan, PhD, et al., Swinburne University of Technology, Australia, in Feb. 5 JAMA. Letter addresses recent study by Solomon et al. which found ginkgo caused no cognitive function improvement in healthy adults (1"The Tan Sheet" Aug. 26, 2002, p. 14). Nathan et al. suggest the selection of tests by Solomon et al. "may not be suitable to outcome studies of complementary therapies such as ginkgo, which generally produce only a mild to moderate benefit with continued use." Five letters appearing in JAMA challenge the study's blinding, focus on healthy individuals. Solomon et al. maintain their trial addressed manufacturer's claims, did not intend to take on herb's effects on impaired population...
You may also be interested in...
Ginkgo Study Shows “No Measurable Benefit” For Memory, Cognition
Daily doses of ginkgo biloba for six weeks resulted in "no significant difference for any outcome measure" versus placebo in approximately 200 adults over age 60 with healthy cognitive function in a study published in the Aug. 21 Journal of the American Medical Association.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.